Financiere des Professionnels Fonds d investissement inc. Buys 24,182 Shares of Kenvue Inc. (NYSE:KVUE)

Financiere des Professionnels Fonds d investissement inc. raised its position in shares of Kenvue Inc. (NYSE:KVUEFree Report) by 15.9% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 176,027 shares of the company’s stock after acquiring an additional 24,182 shares during the period. Financiere des Professionnels Fonds d investissement inc.’s holdings in Kenvue were worth $3,778,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Park Avenue Securities LLC raised its holdings in shares of Kenvue by 11.1% in the first quarter. Park Avenue Securities LLC now owns 36,322 shares of the company’s stock worth $779,000 after buying an additional 3,625 shares during the period. Czech National Bank boosted its stake in shares of Kenvue by 0.5% during the first quarter. Czech National Bank now owns 303,251 shares of the company’s stock valued at $6,508,000 after purchasing an additional 1,392 shares during the period. Fulton Bank N.A. grew its holdings in shares of Kenvue by 22.0% in the first quarter. Fulton Bank N.A. now owns 74,715 shares of the company’s stock worth $1,603,000 after purchasing an additional 13,484 shares during the last quarter. Thomasville National Bank increased its stake in Kenvue by 10.5% in the 1st quarter. Thomasville National Bank now owns 618,690 shares of the company’s stock worth $13,277,000 after buying an additional 58,874 shares during the period. Finally, Renaissance Capital LLC lifted its holdings in Kenvue by 2.3% during the 1st quarter. Renaissance Capital LLC now owns 929,839 shares of the company’s stock valued at $19,954,000 after buying an additional 20,891 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 1.6 %

Kenvue stock traded down $0.31 during mid-day trading on Friday, hitting $18.53. The company’s stock had a trading volume of 63,342,101 shares, compared to its average volume of 17,993,852. The firm has a market capitalization of $35.48 billion and a PE ratio of 23.73. Kenvue Inc. has a 1 year low of $17.75 and a 1 year high of $26.74. The stock’s fifty day moving average is $19.27 and its two-hundred day moving average is $20.04. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUEGet Free Report) last issued its earnings results on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.03. Kenvue had a net margin of 9.63% and a return on equity of 21.06%. The firm had revenue of $2.89 billion for the quarter, compared to analysts’ expectations of $3.79 billion. The business’s revenue for the quarter was down 24.9% on a year-over-year basis. On average, analysts anticipate that Kenvue Inc. will post 1.17 EPS for the current year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 4.32%. The ex-dividend date of this dividend was Tuesday, May 7th. Kenvue’s payout ratio is 102.56%.

Analyst Upgrades and Downgrades

KVUE has been the topic of a number of research analyst reports. The Goldman Sachs Group initiated coverage on shares of Kenvue in a research note on Friday, March 1st. They issued a “neutral” rating and a $20.00 target price on the stock. Sanford C. Bernstein started coverage on Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price objective for the company. HSBC increased their target price on shares of Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a report on Wednesday, May 8th. Citigroup restated a “neutral” rating and issued a $21.00 price target on shares of Kenvue in a report on Tuesday, May 28th. Finally, William Blair assumed coverage on shares of Kenvue in a research note on Wednesday, April 3rd. They set a “market perform” rating on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Kenvue currently has a consensus rating of “Hold” and a consensus target price of $23.09.

Get Our Latest Stock Analysis on Kenvue

Kenvue Company Profile

(Free Report)

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.

Further Reading

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUEFree Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.